13.02
13.02 (0%)
As of Feb 14, 2025
Assembly Biosciences, Inc. [ASMB]
Source:
Company Overview
Assembly Biosciences, Inc is a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor; and (3) a highly potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (833)509-4583 |
| Industry | manufacturing |
| CEO | Jason A. Okazaki |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $28.5 |
| Operating Profit | $-45.4 |
| Net Income | $-40.2 |
| Net Cash | $18.5 |
Profit Ratios
| Gross Margin | $28.5 |
| Operating Margin | -159.3 |
| Profit as % of Revenues | -71% |
| Profit as % of Assets | -31.4% |
| Profit as % of Stockholder Equity | -120.4% |
Management Effectiveness
| Return on Equity | -120.4% |
| Return on Assets | -33.7% |
| Turnover Ratio | 22.3% |
| EBITA | $-45.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $119.2 |
| Total Liabilities | $85.8 |
| Operating Cash Flow | $-51.1 |
| Investing Cash Flow | $40.2 |
| Financing Cash Flow | $29.4 |
